Science Immunology Review Time

AAAS gives a clear picture of editorial level and journal identity, but not a polished public turnaround dashboard.

The public materials tell you:

• Science Immunology is a Science-family journal for critical advances across immunology
• the journal is broad across systems, including human work
• the journal is selective and monthly
• the journal is built for high-consequence immunology rather than ordinary specialty throughput

They do not tell you:

• a clean public median time to first decision
• a public median submission-to-acceptance clock
• a direct split between desk triage and reviewed manuscripts on the journal homepage

That means the safest author model comes from pairing the official AAAS scope with the current SciRev timing layer.

That is the real planning model. If the manuscript is not obviously a Science Immunology paper, the fast part of the process is usually the rejection.

The journal often feels fast because the editorial screen is not pretending to be democratic. It is making a high-bar first read.

Editors are usually deciding quickly:

• is this a broad immunology advance
• is the main consequence visible without niche context
• is the mechanism strong enough for the claim
• does this really belong in a Science-family immunology lane

If the answer is no, authors often learn that quickly.

The slower cases are the manuscripts good enough to survive the first read.

That longer path usually reflects:

• reviewer demand for stronger mechanistic closure
• papers that are strong but not obviously broad enough on first framing
• work that needs a cleaner field-level consequence argument
• revision cycles where the immunology advance is real but the editorial level still has to be earned

So the timing problem is often not reviewer laziness. It is editorial level.

That profile fits the timing pattern. A journal with this editorial position does not need to review every good paper fully.

This comparison matters because many timing disappointments are really owner-journal mistakes.

For year-over-year impact factor data, see the science immunology impact factor page.

Directionally, the open citation signal is down from 14.04 in 2023 to 13.14 in 2024. That does not mean the journal became soft or slow. It means the post-peak immunology citation environment normalized while the journal stayed elite. Authors should read the timing model through editorial selectivity, not through nostalgia for a hotter citation cycle.

Review-time data hides the most important distinction at this journal:

• a fast desk rejection is often a fit verdict, not an administrative one
• a several-month accepted path often means the journal took the paper seriously
• the real variable is not only speed, but whether the paper is operating at flagship broad-immunology level

That is why timing numbers matter, but the hidden variable is still editorial level.

In our pre-submission review work with Science Immunology manuscripts, the biggest timing mistake is treating the journal like a general reward for strong immunology.

It is not.

The papers that move best here usually have:

• a broad immunology consequence visible on page one
• mechanism strong enough to justify the headline
• relevance that travels beyond one receptor, pathway, or disease niche
• a first read that does not require insider context to feel important

Those traits improve timing because they reduce the chance that the paper dies at desk or stalls in a revision fight over its real level.

In our pre-submission review work on Science Immunology-targeted manuscripts, three patterns most consistently predict slow review at Science Immunology (AAAS). Of manuscripts we screened in 2025 targeting Science Immunology and peer venues, the patterns below are the same ones our reviewers flag in real time. The named editorial-culture quirk: Science Immunology professional editors emphasize cross-disciplinary readability with mechanistic depth; subfield-bounded papers extend revision rounds.

Scope-fit ambiguity in the abstract. Science Immunology editors move fastest on manuscripts whose contribution is obviously aligned with the journal's editorial scope (translational immunology). The named failure pattern: subfield-bounded immunology papers without cross-disciplinary framing extend revision rounds. Check whether your abstract reads to Science Immunology's scope →

Methods package incomplete for the journal's reviewer pool. Science Immunology reviewers expect specific methodological detail. Preliminary mechanistic claims without translational implications extend reviewer consultation. Check if your methods package is reviewer-complete →

Reference-list and clean-citation failure mode. Editorial team at Science Immunology (AAAS) screens reference lists for retracted-paper inclusion. Check whether your reference list is clean against Crossref + Retraction Watch →

Editorial detail (for desk-screen calibration). Verify the current Editor-in-Chief and handling-editor list on the journal's editorial-team page before quoting any name in a submission cover letter. Submission portal: https://cts.sciencemag.org. Manuscript constraints: 125-word abstract limit and 5,000-word main-text cap (Science Immunology enforces during desk-screen). We reviewed each of these constraints against current journal author guidelines (accessed 2026-05-08); evidence basis for the patterns above includes both publicly documented author-guidelines and our internal anonymized submission corpus.

Manusights submission-corpus signal for Science Immunology (AAAS). Of the manuscripts our team screened before submission to Science Immunology and peer venues in 2025, the editorial-culture mismatch most consistent across the cohort is Science Immunology professional editors emphasize cross-disciplinary readability with mechanistic depth; subfield-bounded papers extend revision rounds. In our analysis of anonymized Science Immunology-targeted submissions, the documented review timeline shows a bimodal distribution between manuscripts that clear Science Immunology's scope-fit threshold within the first week and those that get extended editorial-board consultation. Top-line triage is handled by the journal's editorial team; verify the current handling editor on the journal's editorial-team page before quoting any name in a cover letter.

For Science Immunology, speed matters less than broad immunology consequence and mechanistic closure.

That is why the better next reads are:

• Science Immunology submission guide
• Science Immunology impact factor
• How to avoid desk rejection at Science Immunology
• How to choose the right journal for your paper

A Science Immunology fit check is usually more useful than anchoring on the five-day desk number alone.

Science Immunology review time is fast only at the first gate. The journal can reject quickly, but the papers that survive that gate usually enter a real several-month review process. Authors should plan around two clocks: rapid editorial triage and a multi-month path for manuscripts that genuinely look like broad immunology advances.

The Manusights Science Immunology readiness scan. This guide tells you what Science Immunology (AAAS)'s editors look for in the first 1-2 weeks of triage. The review tells you whether YOUR paper passes that check before you submit. We have reviewed manuscripts targeting Science Immunology (AAAS) and peer venues; the named patterns below are the same ones the journal's handling editors and outside reviewers flag at the desk-screen and first-review stages. Median 2.0 months to first decision; desk-screen typically completes within 7 days. 60-day money-back guarantee. We do not train AI on your manuscript and delete it within 24 hours.